May 31 |
Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed
|
May 30 |
Larimar's Friedreich's ataxia asset nomlabofusp chosen for FDA accelerated program
|
May 30 |
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
|
May 21 |
Biggest stock movers today: ZIM, XPEV, PANW, GOTU, and more
|
May 20 |
Larimar stock rallies 24% on FDA removal of partial clinical hold
|
May 20 |
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
|
May 10 |
Companies Like Larimar Therapeutics (NASDAQ:LRMR) Are In A Position To Invest In Growth
|
May 9 |
Larimar Therapeutics files for $300M mixed shelf offering
|
May 9 |
Larimar Therapeutics GAAP EPS of -$0.27 misses by $0.04
|
May 9 |
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
|